Loading
A phase 1/2 trial of ABD-3001 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Advanced BioDesign, now recruiting.
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients is a phase 1/2 interventional study registered as NCT05601726 by Advanced BioDesign, with 36 participants planned, started 2022-11-08 and due to reach its primary completion in 2026-06. Interventions recorded: ABD-3001.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.